drugset / Trial / NCT01065623
Clinical Study to Evaluate the Maximum Tolerated Dose of BAY79-4620 Given Every 2 Weeks to Patients With Advanced Solid Tumors
Non-randomizedSingle-groupOpen-labelTreatment
Summary
Clinical study to determine safety, tolerability, to measure how the drug is metabolized by the body and to determine the maximum tolerated dose of BAY79-4620 given every 2 weeks to patients with advanced solid tumors
Timeline
- Start
- 2010-04
- Primary completion
- 2010-08
- Completion
- 2010-08
Outcome
Outcome not reported
Stopped: “The study was terminated due to safety reasons”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BAY79-4620 | Unknown | 0.15 mg/kg | Intravenous |